AMLX insider buying and SEC filings, explained
Amylyx Pharmaceuticals, Inc. · CIK 1658551
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$152K
Insiders who bought
1
Sold (not marked 10b5-1)
$5.0M
Planned sales (10b5-1)
$1.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 5, 2026 | Planned (10b5-1) | George M. Milne Jr. (Director) sold 30,000 shares at about $27.70 ($831K), marked as a 10b5-1 plan trade. Holdings down 4% to 782,881 shares. | SEC filing Filed Oct 7, 2026, 4:00 PM ET |
| Sep 10, 2026 | Sale | Camille L Bedrosian (Chief Medical Officer) sold 10,028 shares at about $32.39 ($325K). Holdings down 3% to 278,064 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Sep 10, 2026 | Sale | James M. Frates (CFO) sold 10,810 shares at about $32.36 ($350K). Holdings down 4% to 233,625 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Sep 10, 2026 | Sale | Gina Mazzariello (Chief Legal Officer) sold 9,536 shares at about $32.46 ($310K). Holdings down 5% to 190,838 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Sep 10, 2026 | Sale | Joshua B Cohen (CEO and Director) sold 30,464 shares at about $32.19 ($981K). Holdings down 1% to 3,613,123 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Sep 10, 2026 | Sale | Justin B. Klee (CEO and Director) sold 30,464 shares at about $32.18 ($980K). Holdings down 1% to 3,613,056 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Jul 9–10, 2026 | Planned (10b5-1) | Gina Mazzariello (Chief Legal Officer) sold 30,000 shares between Jul 9 and Jul 10 at about $17.97 ($539K), marked as a 10b5-1 plan trade. Holdings down 14% to 179,090 shares. | SEC filing Filed Jul 13, 2026 |
| May 21, 2026 | Purchase (code P) | Karen Firestone (Director) bought 3,800 shares at $13.51 ($51K), reported as a purchase (code P). Holdings up 6% to 66,900 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| Mar 2, 2026 | Sale | Justin B. Klee (CEO and Director) sold 29,282 shares at about $14.47 ($424K). Holdings down 1% to 3,334,616 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Joshua B Cohen (CEO and Director) sold 29,282 shares at about $14.48 ($424K). Holdings down 1% to 3,334,683 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Camille L Bedrosian (Chief Medical Officer) sold 6,461 shares at about $14.58 ($94K). Holdings down 4% to 169,295 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | James M. Frates (CFO) sold 7,909 shares at about $14.52 ($115K). Holdings down 5% to 165,638 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Gina Mazzariello (Chief Legal Officer) sold 6,844 shares at about $14.52 ($99K). Holdings down 5% to 134,430 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 23, 2026 | Sale | Gina Mazzariello (Chief Legal Officer) sold 3,419 shares at about $14.14 ($48K). Holdings down 2% to 141,274 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 2, 2026 | Sale | James M. Frates (CFO) sold 3,557 shares at about $14.65 ($52K). Holdings down 2% to 173,547 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Joshua B Cohen (CEO and Director) sold 15,500 shares at about $14.68 ($228K). Holdings down <1% to 3,363,965 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Gina Mazzariello (Chief Legal Officer) sold 3,448 shares at about $14.65 ($51K). Holdings down 2% to 144,693 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Justin B. Klee (CEO and Director) sold 15,500 shares at about $14.69 ($228K). Holdings down <1% to 3,363,898 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Jan 6, 2026 | Sale | James M. Frates (CFO) sold 3,326 shares at about $11.11 ($37K). Holdings down 2% to 177,104 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Sale | Joshua B Cohen (CEO and Director) sold 7,715 shares at about $11.09 ($86K). Holdings down <1% to 3,317,632 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Sale | Justin B. Klee (CEO and Director) sold 7,715 shares at about $11.09 ($86K). Holdings down <1% to 3,317,586 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 8, 2026 |
| Dec 23, 2025 | Purchase (code P) | Karen Firestone (Director) bought 8,100 shares at $12.45 ($101K), reported as a purchase (code P). Holdings up 15% to 63,100 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 23, 2025 |
| Dec 1, 2025 | Sale | Camille L Bedrosian (Chief Medical Officer) sold 6,580 shares at about $14.35 ($94K). Holdings down 4% to 175,756 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 3, 2025 |
21 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AMLX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.